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Relationships (SAR)Abstract A new sequence of pyrazole derivatives (1–6) was synthesized from condensation tech-
nique under utilizing ultrasound irradiation. Synthesized compounds were characterized from IR,
1H NMR, 13C NMR, Mass and elemental analysis. Synthesized compounds (1–6) were screened
for antimicrobial activity. Among the compounds 3 (MIC: 0.25 lg/mL) was exceedingly antibacte-
rially active against gram negative bacteria of Escherichia coli and compound 4 (MIC: 0.25 lg/mL)
was highly active against gram positive bacteria of Streptococcus epidermidis compared with stan-
dard Ciproﬂoxacin. Compound 2 (MIC: 1 lg/mL) was highly antifungal active against Aspergillus
niger proportionate to Clotrimazole. Synthesized compounds (1–6) were screened for anti-
inﬂammatory activity and the compound 2-((5-hydroxy-3-methyl-1H-pyrazol-4-yl)(4-nitrophenyl)
methyl)hydrazinecarboxamide (4) was better activity against anti-inﬂammatory when compared
with standard drugs (Diclofenac sodium). Compounds (2, 3 and 4) are the most important molecules
and hence the need to develop new drugs of antibacterial, antifungal and anti-inﬂammatory agents.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The pyrazole moiety is a versatile lead molecule in the pharma-
ceutical development and has a wide range of biologicalactivities (Goda et al., 2003; El-Emary, 2006; Mansour et al.,
2003), antibacterial (Sangapure et al., 2001), antifungal
(Gupta et al., 2005; Ashish et al., 2006) and pharmacological
activities such as anti-inﬂammatory (Makhsumov et al.,
1986), antitubercular (Chetan and Mulwar, 2000), anticancer
(Nimavat and Popat, 2007), analgesic (Udupi et al., 1998),
antipyretic (Fabiane et al., 2002), anticonvulsant (Ashok
et al., 2001) activities.
Commercially available pyrazole moiety (Fig. 1) such as
Celecoxib is potent COX-2 inhibitor (Penning et al., 1997).
Some other examples of pyrazole derivatives as NSAID are
ramifenazone (Fioravanti et al., 2010), Lonazolac (NSAID)
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Figure 1 The structures of some drugs bearing the pyrazole moiety.
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Compound (phenylbutazone) is a non steroidal drug (Reed
et al., 1985; Vennerstorm et al., 1987). Pyrazofurin is potential
of antiviral activity, HCV virus (Rostom et al., 2003; Riyadh
et al., 2010; Popovici-Muller et al., 2009; Farghaly et al.,
2011). In the current research, anti-inﬂammatory drug has
been used in most prominent research areas. New anti-
inﬂammatory drugs were previously used in clinical research,
some of the drugs are still not efﬁcient and have intolerable
side effects.
Based on the above study, we need to develop new drugs
against anti-inﬂammatory and antimicrobial activities.
Therefore, we were led to identify new approaches of pyrazole
derivatives as well as test the antimicrobial and anti-
inﬂammatory activity.2. Methods and materials
2.1. Chemicals and reagents
All chemicals were acquired from Sigma–Aldrich Chemical Co
(Sigma–Aldrich Corp., St. Louis, MO, USA). The Infrared
spectra (KBr), Proton NMR, Carbon NMR, Mass spectra
(EI), and Elemental analysis (C, H, N and S) were recorded
using Shimadzu 8201PC (4000–400 cm1), Bruker DRX-
400 MHz, Jeol JMS D-300 spectrometer operating, and
Elementer analyser model (Varian EL III).2.1.1. Synthesis of 2-((5-hydroxy-3-methyl-1H-pyrazol-4-yl)
(phenyl)methyl)hydrazinecarboxamide (1)
A mixture of 5-hydroxy-3-methyl-1H-pyrazoles (0.1 mol), ben-
zaldehyde (0.1 mol) and semicarbazide hydrochloride (0.1 mol)
was treated with ultrasound irradiation under ethanol med-
ium. After completion of reaction, the product was isolated
and identiﬁed by TLC. The identiﬁed product was separated
from column chromatography and recrystallized by suitable
solvent. The above experiential procedure was pursued by
remaining compounds 2–6.
IR (cm1): 3445 (C–OH), 670(–CH–), 1679 (NH CO), 1569
(NH2).
1H NMR (DMSO-d6): d 9.90 (s, 1H, C–OH), 2.71 (d,
J= 4.4 Hz, 1H, CH), 2.23(s, 3H,CH3), 4.45 (dd, J= 5.3 Hz,
1H, –CH–), 7.33–7.49 (m, 5H, Phenyl ring), 2.36
(d, J= 2.0 Hz, 1H, NH), 6.81 (d, J= 1.4 Hz, 1H, NH), 6.25
(s, 2H, NH2).
13C NMR (CDCl3): d 167.2(C–OH), 162.6
(C–CH3), 42.2(C–CH–), 52.3(C–CH–NH), 18.7(C–CH3),
155.4(CONH2), 141.7, 112.0, 129.2, 133.8 (Phenyl ring).
Mass (m/z): 261.27 (M+, 32%), 244.28, 216.38, 200.27
(100%), 185.26, 170.25, 94.15.
2.1.2. 2-[(4-chlorophenyl)(3-hydroxy-5-methyl-4H-pyrazol-4-yl)
methyl]hydrazinecarboxamide(2)
IR (cm1): 3469 (C–OH), 691(–CH–), 1665 (NH CO),
1554(NH2), 897(C–Cl).
1H NMR (DMSO-d6): d 9.96(s, 1H,
C–OH), 2.76 (d, J= 4.3 Hz, 1H, CH), 2.29 (s, 3H, CH3),
4.30(dd, J= 5.2 Hz, 1H, –CH–), 7.21–7.39 (dd, 4H, Phenyl
ring), 2.31 (s, J= 2.1 Hz, 1H, NH), 6.73 (s, J= 1.6 Hz, 1H,
616 R. Surendra Kumar et al.NH), 6.19 (s, 2H, NH2).
13C NMR (CDCl3): d 167.2 (C–OH),
162.6 (C–CH3), 42.2 (C–CH–), 52.3 (C–CH–NH), 18.7
(C–CH3), 155.4 (CONH2), 141.7, 112.0, 129.2, 133.8 (Phenyl
ring). Mass (m/z): 295.72(M+, 26%), 277.74, 243.30 (100%),
228.28, 200.27, 185.26, 170.25, 94.15.
2.1.3. 2-((3-hydroxy-5-methyl-4H-pyrazol-4-yl)
(4-hydroxyphenyl)methyl)hydrazinecarboxamide (3)
IR(cm1): 3457(C–OH), 682(–CH–), 1661(NHCO),
1508(NH2), 1447(OH).
1H NMR(DMSO-d6): d 9.89 (s, 1H,
C–OH), 2.70(d, J= 4.1 Hz, 1H,CH), 2.31 (s, 3H, CH3),
4.36(dd, J= 5.6 Hz, 1H, –CH–), 7.23–7.31 (dd, 4H, Phenyl
ring), 2.33 (s, J= 2.3 Hz, 1H, NH), 6.70 (s, J= 1.6 Hz, 1H,
NH), 6.21 (s, 2H, NH2).
13C NMR (CDCl3): d 167.9 (COH),
163.2 (C2–CH3), 42.6 (C–CH–), 51.9 (C–CH–NH), 18.5
(C–CH3), 155.0 (CONH2), 146.7, 111.5, 128.2, 137.2 (Phenyl
ring). Mass (m/z): 277.27(M+, 22%), 259.30, 243.42(100%),
228.28, 200.27, 185.26, 170.25.
2.1.4. 2-[(3-hydroxy-5-methyl-4H-pyrazol-4-yl)
(4-nitrophenyl)methyl]hydrazinecarboxamide (4)
IR(cm1); 3450 (C–OH), 679(–CH–), 1660 (NHCO),
1514(NH2), 1536(C–NO2).
1H NMR (DMSO-d6): d9.91
(s, 1H, C–OH), 2.79(d, J= 4.6 Hz, 1H, CH), 2.32 (s,
3H, CH3), 4.41 (dd, J= 5.2 Hz, 1H, –CH–), 7.29–7.42
(dd, 4H, Phenyl ring), 2.39 (d, J= 2.1 Hz, 1H, NH),
6.81 (d, J= 1.7 Hz, 1H, NH), 6.26 (s, 2H, NH2).
13C
NMR (CDCl3): d167.1(C–OH), 162.9(C–CH3), 42.0
(C–CH–), 52.6 (C–CH–NH), 19.8 (C–CH3), 156.3
(CONH2), 142.9, 112.5, 128.2, 131.2 (Phenyl ring). Mass
(m/z): 306.27(M+, 26%), 289.28, 261.27, 245.27(100%),
200.27, 185.26, 170.25.
2.1.5. 2-[(3-hydroxy-5-methyl-4H-pyrazol-4-yl)(4-methoxy
phenyl)methyl]hydrazine carboxamide(5)
IR (cm1): 3460 (C–OH), 682(–CH–), 1668 (NHCO),1508
(NH2).
1H NMR (DMSO-d6): d 9.92 (s, 1H, C–OH), 2.76 (d,
J= 4.1 Hz, 1H, CH),2.36 (s, 3H, CH3),4.28 (dd, J= 5.5 Hz,
1H, –CH–),7.19–7.25 (dd, 4H, Phenyl ring), 2.39 (d,
J= 2.2 Hz, 1H, NH), 6.84(d, J= 1.5 Hz,1H, NH),
6.15(s,2H, NH2).
13C NMR (CDCl3): d 167.3 (C–OH), 162.0
(C–CH3), 42.9 (C–CH–), 53.1 (C–CH–NH), 19.1 (C–CH3),
156.8 (CONH2),141.7,112.0,129.2, 133.8 (Phenyl ring). Mass
(1 m/z): 291.30(M+, 41%), 259.30, 243.30, 200.27(100%),
185.26, 170.25, 94.15.
2.1.6. 2-((4-(dimethylamino)phenyl)(3-hydroxy-5-methyl-4H-
pyrazol-4-yl)methyl)hydrazinecarboxamide (6)
IR (cm1): 3451 (C–OH), 663(–CH–), 1679 (NHCO),
1512 (NH2).
1H NMR (DMSO-d6): d 9.95 (s, 1H,
C–OH), 2.76 (d, J= 4.3 Hz, 1H, CH), 2.24 (s, 3H,
CH3), 4.41(dd, J= 5.6 Hz, 1H, –CH–),7.29–7.41 (dd,
4H, Phenyl ring), 2.36 (d, J= 2.3 Hz, 1H, NH), 6.82(d,
J= 1.9 Hz, 1H, NH), 6.17 (s, 2H, NH2).
13C NMR
(CDCl3): d167.9 (C–OH), 162.5(C–CH3), 43.1(C–CH–),
54.6 (C–CH–NH), 18.9(C–CH3), 157.1 (CONH2), 142.8,
113.0, 127.2, 134.1 (Phenyl ring). Mass (m/z): 304.34
(M+, 27%), 286.37, 276.30, 243.34(100%), 200.27,
185.26, 170.25, 94.15.2.2. Pharmacological activity
2.2.1. Anti-inﬂammatory activity
Isolated compounds (1–6) were evaluated by anti-
inﬂammatory activity, screening method followed from the lit-
erature method (Winter et al., 1962). Albino rats of both sexes
weighing 150 g were divided into 4 groups, each group consists
of 5 animals. Inﬂammation was induced by intra planter injec-
tion of histamine (0.1 mL of 1% histamine for induction of
paw edema). The rats are challenged by s.c injection of
0.1 mL of 1% solution of histamine into the sub-plantar side
of the left hind paw. 1 h after the administration of the test
compounds (10 mg/kg; p.o), one group was kept as control,
received only 0.5% carboxy methyl cellulose solution. The vol-
ume was measured before and after 3 h of carrageen treatment
by means of plethysmometer.
The percentage of anti-inﬂammatory activity was calcu-
lated by = (Vc  Vt/Vc) · 100.Vc = control, Vt = test
sample.
2.2.2. In vitro antibacterial screening
The antibacterial screening for isolated compounds was deter-
mined by the disc diffusion method (Bauer et al., 1996) using
Mueller–Hinton agar (Hi-Media) medium. The synthesized
compounds were evaluated against gram negative bacteria of
Escherichia coli (MTCC-739), Pseudomonas aeruginosa
(MTCC-2435), Klebsiella pneumonia (recultured) and gram
positive bacteria of Streptococcus epidermidis, Staphylococcus
aureus (MTCC-96). Synthesized compounds were initially
screened by maximum concentration at 100 lg/mL in
DMSO. The zone of inhibition was measured after 24 h incu-
bation at 37 C. The MIC was identiﬁed by twofold dilutions
of the solution method (64, 32. . .., 0.5 lg/mL).
2.2.3. In vitro antifungal screening
The antifungal screening for isolated compounds was deter-
mined by using the disc diffusion method (Verma et al.,
1998) with Sabouraud’s dextrose agar (Hi-Media). The iso-
lated compounds were estimated for their in vitro antifungal
activity against Aspergillus niger, Candia albicans,
Microsporum audouinii and Cryptococcus neoformans (recul-
tured). Synthesized compounds were initially screened by max-
imum concentration at 100 lg/mL in DMSO. The zone of
inhibition (mm) was measured after incubation at 37 C. The
MIC was identiﬁed by twofold dilutions of the solution
method (64, 32. . .., 0.5 lg/mL).
3. Results
3.1. Synthesis and characterization of pyrazole analogues
Title compounds (1–6) were synthesized from 5(3)-hydroxy-
3(5)-methyl-1H-pyrazoles reacting with aldehyde and semicar-
bazide via Ultrasound irradiation under aqueous medium and
without catalysis condition, the synthetic route of pyrazole
derivatives is represented in Scheme 1. The compounds (1–6)
were manufactured by Mannich base condensation method
and the mechanism of the work outlined in Scheme 1.
Physicochemical data of the compounds (1–6) are given in
Table 1.
))))))
+ +
H2N NH
NH2
O
NHN
CH3HO
NH
HN
H2N
O
HN N
O CH3
R
CHO
R
Scheme 1 Synthetic route of the isolated compounds (1–6).
Table 1 Physicochemical data of the compounds (1–6).
Comp. No. Ar Yield % mpC m.f m.w Elemental analysis calculated (found)
C H N
1 –H 87 161 C12H15N5O2 261.27 55.16 (55.20) 5.79 (5.71) 26.80 (26.79)
2 –Cl 78 89 C12H14ClN5O2 295.72 44.74 (44.72) 4.77 (4.76) 23.68 (23.65)
3 –OH 81 121 C12H15N5O3 277.27 51.98 (51.97) 5.45 (5.40) 25.26 (25.23)
4 –NO2 72 134 C12H14N6O4 306.27 47.06 (47.10) 4.61 (4.59) 27.44 (27.43)
5 –OCH3 81 110 C13H17N5O3 291.30 53.60 (53.65) 5.88 (5.86) 24.04 (24.08)
6 –N(CH3)2 85 97 C14H20N6O2 304.34 55.25 (55.30) 6.62 (6.60) 27.61 (27.60)
Anti-inﬂammatory and antimicrobial activities of novel pyrazole analogues 617Isolated compounds were characterized by Infra red,
Proton NMR, Carbon NMR spectrum, Mass spectra, and ele-
mental analyses.
Compound 1 was conﬁrmed by IR spectral analysis, which
indicates the value of 3445 cm1 corresponding to the OH
group nearby in the pyrazole ring and another absorption
band at 670 cm1 corresponding to the –CH– group presented
in the pyrazole ring. Another analysis of 1H NMR spectrum
shows the signals observed at d 13.03, 11.43, 5.45, 2.36, and
6.25 corresponding to NH in the pyrazole ring, C–OH,
–CH–, NH, CH, and NH2 protons respectively and
13C
NMR spectrum shows that peaks at d 132.2, 51.2, and 12.7
correspond to C–OH, C–CH–NH, and CH3 carbons respec-
tively. Molecular mass of compound 1 was conﬁrmed by mass
spectral analysis, which is indicated that the molecular ion
peaks at 261.27(M+, 32%).
3.2. Anti-inﬂammatory activity
Isolated products (1–6) were evaluated for anti-inﬂammatory
activity match up with diclofenac sodium at oral dose. Rat
albino was used as an oral dose of the test compound at a con-
centration of 10 mg/kg, the percentage of the activity was mea-
sured at 3 h. Compound (4) is highly active compared with
standard. Fig. 2 shows the activity difference of compounds
(1–6), anti-inﬂammatory activity records are presented in
Table 2.
3.3. Antibacterial activity
Compound (3) is exceedingly active (MIC: 0.25 lg/mL) against
gram negative bacteria of E. coli compared with Ciproﬂoxacin
MIC: 0.5 lg/mL. Compound (4) (MIC: 0.25 lg/mL) is highlyactive and match up with standard (MIC: 4 lg/mL) against
gram-negative bacteria of S. epidermidis. The bacterial zones
of inhibition values are presented in Table 3 and Fig. 3 indi-
cates differentiation of antibacterial activity in isolated com-
pounds (1–6).
3.4. Antifungal activity
Compound (2) MIC: 1 lg/mL is greatly active against A. niger
match up to with Clotrimazole MIC: 2 lg/mL. Compound (3)
(MIC: 0.5 lg/mL) has equipotent activity against M. audouinii
match up to with standard Clotrimazole (MIC: 0.5 lg/mL)
whereas compound 5 (MIC: 4 lg/mL) is moderately active
against A. niger. The fungal zones of inhibition values are pre-
sented in Table 4. Fig. 4 indicates differentiation of antifungal
activity in isolated compounds of compounds (1–6). Minimal
inhibitory concentration (MIC) data are reported in Table 5.
4. Discussion
The anti-inﬂammatory and antimicrobial performances of the
isolated compounds were conﬁrmed by structure–activity rela-
tionships (Fig. 5).
The 4-substituted phenyl ring with semicarbazone acts as a
lipophilic and hydrogen bonding domain. Therefore, the above
group containing the pyrazole ring may be stated as the essen-
tial pharmacophoric requirement for anti-inﬂammatory
activity.
(i) Compound 3 (MIC: 0.25 lg/mL) pyrazole derivative
exhibited high activity against gram negative E. coli compared
with standard Ciproﬂoxacin and also antifungal activity of
compound 3 exhibited equipotent activity (MIC: 0.5 lg/mL)
against M. audouinii match up to with standard Clotrimazole
Figure 2 Anti-inﬂammatory activity of compounds (1–6).
Table 2 Anti-inﬂammatory activity of compounds (1–6).
Comp.
No
Increase in paw
volume (3hr – 0hr)
Percentage (%) of Activity,
Dose (10 mg/ kg)
Control 0.56 –
1 0.22 ± 0.05 66.0*
2 0.18 ± 0.06 67.8*
3 0.32 ± 0.06 42.8*
4 0.10 ± 0.02 82.1*
5 0.38 ± 0.09 32.1*
6 0.41 ± 0.02 26.7*
Standard 0.14 ± 0.01 75.0*
Mean ± SEM, n= 6 in each group. Signiﬁcance levels *P< 0.01
as compared with the respective control. Diclofenac sodium was
used as a standard.
Table 3 Antibacterial activity of isolated products (1–6).
Compounds Gram-negative
E. coli P. aeruginosa
1 12 –
2 16 –
3 28 8
4 20 –
5 18 12
6 15 –
Standard 26 17
Ciproﬂoxacin used as a standard, zone of inhibition measured at (mm).
Figure 3 Antibacterial activ
618 R. Surendra Kumar et al.(MIC: 0.5 lg/mL), reason of activity due to the presence of 4-
OH-phenyl with semicarbazone and pyrazole moiety in com-
pound 3. (ii) Compound 2 (MIC: 1 lg/mL) is highly active
against gram negative bacteria of K. pneumoniae and also
highly active (MIC: 1 lg/mL) against A. niger compared with
standard Clotrimazole (MIC: 2 lg/mL) in antifungal screening,
4-Cl-phenyl with semicarbazone and pyrazole moiety were rep-
resented to be highly active against K. pneumoniae bacterial and
A. niger fungal strain. (iii) Compound 4 is highly active (MIC:
2 lg/mL) against gram positive bacteria of S. epidermidis com-
pared with standard Ciproﬂoxacin (MIC: 4 lg/mL), reason of
activity due to the presence of 4-NO2-phenyl with semicar-
bazone and pyrazole moiety in compound 4. The compound
4 is very much active (82%) against anti-inﬂammatory in rela-
tion to Diclofenac sodium 74.0% of activity.Gram-positive
K. pneumoniae S. aureus S. epidermidis
– – 12
18 – 16
– 10 10
8 12 18
10 - 12
– 14 14
19 22 15
ity of compounds (1–6).
Table 4 Antifungal activity of isolated products (1–6).
Compounds A. niger C. albicans C. neoformans M. audouinii
1 10 – – 12
2 24 12 – 18
3 15 16 8 25
4 14 10 – 10
5 20 12 10 12
6 18 – – 10
Standard 22 24 25 26
Clotrimazole used as a standard, zone of inhibition measured at (mm).
Figure 4 Antifungal activity of compounds (1–6).
Table 5 Minimum inhibition concentration of isolated products (2, 3 and 5).
Comp. No. E. c P. a K. p S. a S. e A. n C. a C. n M. a
2 64 >100 1 >100 16 1 64 >100 16
3 0.25 64 >100 64 64 64 64 >100 0.5
4 16 >100 >100 64 2 64 >100 >100 >100
5 16 32 64 >100 16 4 64 64 32
Ciproﬂoxacin 0.5 1 2 0.5 4 – – – –
Clotrimazole – – – – – 2 1 0.5 0.5
NH N
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CH3
NH
NH2
O
OH
NH N
OH
NH
CH3
NH
NH2
O
Cl
NH N
OH
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Figure 5 Structure–activity relationships for compounds (3, 2 and 4).
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In conclusion, synthesized compounds (1–6) were tested with
anti-inﬂammatory and antimicrobial screening. Among the
series, compound (3) (MIC : 0.25 lg/mL) was found to be
the most active against gram negative bacterial strain E. coli
compared with standard Ciproﬂoxacin, antifungal activity of
compound (2) (MIC: 1 lg/mL) was greatly active against A.
niger than standard Clotrimazole and compound (4) showed
better activity against anti-inﬂammatory when compared with
Diclofenac sodium. Therefore these derivatives could provide
as a highly momentous molecule for further development of
antimicrobial, anti-inﬂammatory agents.
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